09:48 AM EDT, 06/06/2024 (MT Newswires) -- Takeda Pharmaceutical's ( TAK ) unit Takeda Canada has partnered with HEALWELL AI's subsidiary Pentavere Research Group to analyze real-world evidence for rare diseases in Canada, HEALWELL said Thursday.

The focus of the collaboration will be on supporting patients with hereditary angioedema, or HAE, with normal C1 inhibitor, an ultra-rare condition marked by recurrent life-threatening swelling, the company said.

Shares of Takeda Pharmaceutical ( TAK ) were down 0.1% in early Thursday trading.

Price: 13.50, Change: -0.02, Percent Change: -0.11